AVI BioPharma’s Drug Candidate Receives European Orphan Drug Designation

AVI BioPharma, Inc., a developer of RNA-based drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy.
CNNMoney